Biocon on Tuesday reported a net profit of Rs 85 crore for the quarter ended September 30, 2025, compared to a loss of Rs 16 crore a year earlier, driven by strong biosimilar sales and improved operating leverage.
Profit before tax (PBT), excluding exceptional items, rose 153% to ₹183 crore.
Consolidated revenue grew 11% year-on-year to Rs. 4,389 crore, led by a 25% jump in biosimilars, which contributed 61% of segmental revenue. Biocon's biosimilar reported Rs 2,721 crore.
The company’s EBITDA rose 29% to ₹928 crore, with margins expanding to 21%. Core EBITDA, excluding R&D and forex impacts, stood at ₹1,218 crore with a 28% margin.
Generics grew 24%, while Syngene’s CRDMO business rose 2%.
“Biocon Biologics delivered a strong performance with over 40% EBITDA growth and 11% sequential revenue growth,” said Shreehas Tambe, CEO of Biocon Biologics. “We launched four biosimilars globally and remain on track for the bDenosumab lunch.”
Debt restructuring and US expansionBiocon said it settled structured debt obligations with Goldman Sachs and Kotak using QIP proceeds and signed an agreement with Edelweiss, which is expected to lower interest costs and improve profitability from FY27.
In a strategic move, Biocon inaugurated its first U.S. manufacturing facility in Cranbury, New Jersey, with a $30 million investment. The oral solid dosage (OSD) plant has a capacity of 2 billion tablets annually.
The generics business saw traction from new launches including Liraglutide, Dasatinib, and Sacubitril + Valsartan, with R&D spend at 9% of segment revenue. Syngene’s CRDMO unit secured its first global Phase III trial and expanded its clinical footprint to Australia, UK, and Eastern Europe.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
